Paclitaxel.
Analysis
Cancer
Paclitaxel
Physicochemical
Taxus
Journal
Profiles of drug substances, excipients, and related methodology
ISSN: 1871-5125
Titre abrégé: Profiles Drug Subst Excip Relat Methodol
Pays: Netherlands
ID NLM: 101197857
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
29
4
2019
pubmed:
29
4
2019
medline:
1
8
2019
Statut:
ppublish
Résumé
Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and cervical carcinoma. It is also used for treating AIDS-related Kaposi sarcoma as a second line treatment. This comprehensive profile of paclitaxel gives overview of nomenclature, formulae, elemental analysis, appearance, application and uses. In addition, mechanism of action and resistance, different dosage forms and methods of drug preparation are elaborated. Moreover, the physicochemical properties involving X-ray powder diffraction pattern, drug solubility, melting point, differential scanning calorimetry, and stability were summarized. Furthermore, method of drug analysis including compendial, spectrophotometric, and chromatographic was discussed.
Identifiants
pubmed: 31029218
pii: S1871-5125(18)30016-5
doi: 10.1016/bs.podrm.2018.11.001
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Powders
0
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Pagination
205-238Informations de copyright
© 2019 Elsevier Inc. All rights reserved.